Metal-Organic Frameworks for Highly Selective Separation of Xylene Isomers and Single-Crystal X-ray Study of Aromatic Guest-Host Inclusion Compounds.

Separation of hydrocarbon molecules, such as benzene/cyclohexane and o-xylene/m-xylene/p-xylene, is relevant due to their widespread application as chemical feedstock but challenging because of their similar boiling points and close molecular sizes. Physisorption separation could offer an energy-efficient solution to this problem, but the design and synthesis of sorbents that exhibit high selectivity for one of the hydrocarbons remain a largely unmet challenge. Herein, we report a new heterometallic MOF with a unique tortuous shape of channels decorated with aromatic sorption sites [Li2Zn2(bpy)(ndc)3] (NIIC-30(Ph), bpy = 4,4'-bipyridine, ndc2- = naphthalene-1,4-dicarboxylate) and study of its benzene/cyclohexane and xylene vapor and liquid separation. For an equimolar benzene/cyclohexane mixture, it is possible to achieve a 10-fold excess of benzene in the adsorbed phase. In the case of xylenes, microporous framework NIIC-30(Ph) demonstrates outstanding selective sorption properties and becomes a new benchmark for m-/o-xylene separation. In addition, NIIC-30(Ph) is stable enough to carry out at least three separation cycles of benzene/cyclohexane mixtures or ternary o-xylene/m-xylene/p-xylene mixtures both in the liquid and in the vapor phase. Insights into the performance of NIIC-30(Ph) are gained from X-ray structural studies of each aromatic guest inclusion compound.

Therapeutic approaches to gastroesophageal junction adenocarcinomas.

The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the distinction between adenocarcinomas above, below, or within the gastroesophageal junction; combined modality therapy; tumor markers for use in personalized medicine; PET-CT and endoscopic biopsies in the evaluation of response to neoadjuvant chemoradiation therapy; a standardized grading system for tumor regression in squamous cell cancer and adenocarcinoma; the experimental basis for new approaches to medical treatment; the criteria measuring response in esophageal cancer; and the impact of novel imaging on staging and response assessment.

Tamoxifen non-estrogen receptor mediated molecular targets.

Recent experimental studies revealing new biological effects of tamoxifen on tumor cells both expressing and not expressing different types of estrogen receptors (ERα and ERß) show new aspects of a seemingly well known agent. This review describes tamoxifen targets, the blocking of which leads to inhibition of tumor cell growth and angiogenesis, stimulation of programmed cell death (apoptosis, autophagia and necrosis), inhibition of multidrug resistance, invasion and metastasis. Since outcomes of tamoxifen action on cells are prognostically good from the point of view of both tumor growth/metastasis inhibition and tumor response to drug therapy, the authors believe this is an extremely important addition to tamoxifen antiestrogenic effect. Arguments are provided to consider the strategy of long-term tamoxifen treatment proposed by Professor Craig V. Jordan in the 1970s that is also applicable to the treatment of other tumors. This is, first of all, the fact that expression of estrogen receptor-beta that can also be targeted by tamoxifen therapy in solid tumors of practically all known sites and histologies. The authors believe that molecular biological screening of patients with respect to expression of tamoxifen cellular targets other than ERα and ERß is needed to use to the full all tamoxifen biological activities other than modulation of estrogen receptors during long-term adjuvant therapy for cancers of various sites.